Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 98 | 2024 | 5686 | 10.020 |
Why?
|
Carcinoma, Squamous Cell | 54 | 2024 | 4034 | 7.100 |
Why?
|
Carcinoma, Basal Cell | 22 | 2024 | 545 | 6.540 |
Why?
|
Keratosis, Actinic | 9 | 2024 | 74 | 4.010 |
Why?
|
Dermatologic Agents | 8 | 2019 | 278 | 2.340 |
Why?
|
Dermatology | 12 | 2020 | 872 | 2.270 |
Why?
|
Melanoma | 24 | 2023 | 5510 | 2.100 |
Why?
|
Psoriasis | 8 | 2023 | 898 | 1.840 |
Why?
|
California | 22 | 2018 | 1402 | 1.810 |
Why?
|
Keratinocytes | 13 | 2020 | 798 | 1.760 |
Why?
|
Neoplasms, Multiple Primary | 4 | 2019 | 604 | 1.720 |
Why?
|
Dermatitis, Atopic | 6 | 2023 | 654 | 1.700 |
Why?
|
Mohs Surgery | 5 | 2021 | 197 | 1.500 |
Why?
|
Genetic Loci | 6 | 2020 | 2575 | 1.370 |
Why?
|
Vitamin D | 10 | 2021 | 3223 | 1.160 |
Why?
|
Fluorouracil | 5 | 2023 | 1619 | 1.010 |
Why?
|
Genetic Predisposition to Disease | 13 | 2022 | 17446 | 0.880 |
Why?
|
Skin Pigmentation | 3 | 2020 | 282 | 0.870 |
Why?
|
Organ Transplantation | 7 | 2021 | 1139 | 0.870 |
Why?
|
Needs Assessment | 6 | 2018 | 1147 | 0.860 |
Why?
|
Risk Assessment | 21 | 2023 | 23338 | 0.820 |
Why?
|
Registries | 8 | 2018 | 8089 | 0.780 |
Why?
|
Sunlight | 4 | 2018 | 325 | 0.770 |
Why?
|
Biological Products | 3 | 2021 | 860 | 0.760 |
Why?
|
Papillomaviridae | 4 | 2019 | 1119 | 0.750 |
Why?
|
Carcinoma, Merkel Cell | 5 | 2016 | 300 | 0.750 |
Why?
|
Incidence | 23 | 2024 | 20947 | 0.710 |
Why?
|
Health Services Needs and Demand | 3 | 2012 | 1411 | 0.690 |
Why?
|
Humans | 159 | 2024 | 744343 | 0.670 |
Why?
|
Orphan Drug Production | 1 | 2019 | 50 | 0.660 |
Why?
|
Myotonic Dystrophy | 1 | 2019 | 78 | 0.650 |
Why?
|
Women, Working | 1 | 2019 | 87 | 0.640 |
Why?
|
Cohort Studies | 30 | 2023 | 40561 | 0.610 |
Why?
|
Lentigo | 1 | 2017 | 37 | 0.610 |
Why?
|
Immunosuppressive Agents | 6 | 2021 | 4149 | 0.610 |
Why?
|
Aminoquinolines | 1 | 2017 | 109 | 0.610 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2020 | 392 | 0.610 |
Why?
|
Middle Aged | 68 | 2023 | 213383 | 0.610 |
Why?
|
Aged | 63 | 2024 | 163280 | 0.600 |
Why?
|
Risk Factors | 39 | 2024 | 72290 | 0.600 |
Why?
|
Valproic Acid | 1 | 2020 | 445 | 0.600 |
Why?
|
DNA Virus Infections | 1 | 2017 | 13 | 0.600 |
Why?
|
Hidradenitis Suppurativa | 1 | 2020 | 153 | 0.590 |
Why?
|
Skin Diseases | 3 | 2023 | 1065 | 0.590 |
Why?
|
Genes, MHC Class II | 1 | 2018 | 457 | 0.590 |
Why?
|
Dietary Supplements | 5 | 2014 | 3297 | 0.570 |
Why?
|
Salaries and Fringe Benefits | 1 | 2019 | 264 | 0.570 |
Why?
|
Male | 90 | 2023 | 350118 | 0.570 |
Why?
|
SEER Program | 3 | 2017 | 1508 | 0.570 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 2282 | 0.560 |
Why?
|
Polymorphism, Single Nucleotide | 12 | 2024 | 15519 | 0.550 |
Why?
|
Genome-Wide Association Study | 11 | 2024 | 12261 | 0.520 |
Why?
|
Female | 88 | 2023 | 380194 | 0.520 |
Why?
|
Herpes Zoster | 1 | 2018 | 264 | 0.520 |
Why?
|
Mendelian Randomization Analysis | 1 | 2021 | 967 | 0.520 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2020 | 789 | 0.500 |
Why?
|
Interferon Regulatory Factors | 1 | 2016 | 270 | 0.500 |
Why?
|
Aged, 80 and over | 30 | 2020 | 57776 | 0.490 |
Why?
|
Sex Factors | 6 | 2019 | 10397 | 0.490 |
Why?
|
Rare Diseases | 1 | 2019 | 553 | 0.480 |
Why?
|
Photosensitizing Agents | 1 | 2018 | 602 | 0.480 |
Why?
|
Lithium | 1 | 2017 | 601 | 0.470 |
Why?
|
Managed Care Programs | 3 | 2017 | 950 | 0.470 |
Why?
|
Epidemiologic Methods | 1 | 2019 | 1364 | 0.470 |
Why?
|
Patient Care | 1 | 2019 | 640 | 0.460 |
Why?
|
Evidence-Based Medicine | 3 | 2019 | 3610 | 0.460 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2013 | 84 | 0.460 |
Why?
|
Antihypertensive Agents | 3 | 2018 | 2046 | 0.460 |
Why?
|
Drug Approval | 2 | 2019 | 742 | 0.450 |
Why?
|
Sex Distribution | 6 | 2017 | 2297 | 0.450 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2014 | 104 | 0.450 |
Why?
|
Follow-Up Studies | 17 | 2020 | 39050 | 0.440 |
Why?
|
Physicians, Women | 1 | 2019 | 486 | 0.440 |
Why?
|
Point-of-Care Systems | 1 | 2021 | 1177 | 0.430 |
Why?
|
Neuroectodermal Tumor, Melanotic | 1 | 2012 | 3 | 0.430 |
Why?
|
Adult | 50 | 2023 | 214055 | 0.420 |
Why?
|
Carcinoma, Large Cell | 1 | 2013 | 113 | 0.420 |
Why?
|
Haplotypes | 2 | 2018 | 2779 | 0.420 |
Why?
|
Retrospective Studies | 30 | 2023 | 77449 | 0.420 |
Why?
|
Delivery of Health Care | 4 | 2020 | 5319 | 0.410 |
Why?
|
Early Detection of Cancer | 3 | 2023 | 3086 | 0.410 |
Why?
|
Community Health Services | 1 | 2017 | 650 | 0.410 |
Why?
|
Lymph Node Excision | 2 | 2015 | 1261 | 0.400 |
Why?
|
Carcinoma | 2 | 2020 | 2375 | 0.390 |
Why?
|
HLA Antigens | 1 | 2017 | 1381 | 0.390 |
Why?
|
Glucocorticoids | 1 | 2020 | 2107 | 0.390 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1028 | 0.370 |
Why?
|
Vitamins | 5 | 2021 | 1622 | 0.370 |
Why?
|
Vitamin D Deficiency | 3 | 2021 | 1343 | 0.370 |
Why?
|
Skin Aging | 1 | 2011 | 127 | 0.370 |
Why?
|
Arthritis, Psoriatic | 1 | 2013 | 215 | 0.360 |
Why?
|
Epidermis | 1 | 2012 | 528 | 0.350 |
Why?
|
Tea | 1 | 2011 | 275 | 0.340 |
Why?
|
Bacterial Infections | 1 | 2017 | 1401 | 0.330 |
Why?
|
Opioid-Related Disorders | 2 | 2021 | 2065 | 0.330 |
Why?
|
Carotenoids | 1 | 2012 | 624 | 0.330 |
Why?
|
Vitamin A | 1 | 2012 | 615 | 0.330 |
Why?
|
Confidence Intervals | 6 | 2017 | 2971 | 0.320 |
Why?
|
Databases, Factual | 8 | 2019 | 7729 | 0.320 |
Why?
|
Antigens, Neoplasm | 1 | 2016 | 1988 | 0.320 |
Why?
|
Electronic Health Records | 3 | 2021 | 4468 | 0.320 |
Why?
|
Patient Satisfaction | 2 | 2011 | 3396 | 0.310 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 719 | 0.310 |
Why?
|
Mass Screening | 2 | 2023 | 5255 | 0.310 |
Why?
|
Sirolimus | 1 | 2015 | 1564 | 0.310 |
Why?
|
Proportional Hazards Models | 9 | 2017 | 12354 | 0.310 |
Why?
|
Quality Improvement | 3 | 2020 | 3749 | 0.310 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1061 | 0.300 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 3647 | 0.300 |
Why?
|
Sunbathing | 2 | 2018 | 60 | 0.300 |
Why?
|
Young Adult | 19 | 2023 | 56430 | 0.300 |
Why?
|
Contraceptives, Oral | 1 | 2010 | 564 | 0.300 |
Why?
|
Models, Statistical | 2 | 2019 | 5102 | 0.290 |
Why?
|
Age Distribution | 4 | 2017 | 2902 | 0.290 |
Why?
|
Head Movements | 1 | 2007 | 150 | 0.270 |
Why?
|
Population Surveillance | 1 | 2016 | 2616 | 0.270 |
Why?
|
Administration, Topical | 2 | 2017 | 690 | 0.260 |
Why?
|
Skin | 6 | 2022 | 4364 | 0.260 |
Why?
|
Research Design | 3 | 2019 | 5987 | 0.260 |
Why?
|
Biomedical Research | 2 | 2019 | 3309 | 0.260 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2006 | 85 | 0.260 |
Why?
|
Genomics | 2 | 2019 | 5720 | 0.250 |
Why?
|
Mitochondria | 1 | 2018 | 3520 | 0.250 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3674 | 0.250 |
Why?
|
Calcifediol | 2 | 2018 | 166 | 0.250 |
Why?
|
Models, Biological | 2 | 2019 | 9583 | 0.250 |
Why?
|
Surgery, Plastic | 1 | 2011 | 624 | 0.250 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4251 | 0.240 |
Why?
|
Hemangiosarcoma | 1 | 2007 | 239 | 0.240 |
Why?
|
Quality of Health Care | 1 | 2019 | 4371 | 0.240 |
Why?
|
Odds Ratio | 7 | 2017 | 9849 | 0.230 |
Why?
|
Prognosis | 13 | 2018 | 29063 | 0.230 |
Why?
|
Adolescent | 19 | 2023 | 85781 | 0.230 |
Why?
|
United States | 18 | 2023 | 69872 | 0.220 |
Why?
|
Risk | 4 | 2019 | 9687 | 0.220 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1782 | 0.220 |
Why?
|
Education, Medical, Continuing | 3 | 2019 | 840 | 0.220 |
Why?
|
Lymph Nodes | 1 | 2014 | 3474 | 0.220 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2022 | 14 | 0.220 |
Why?
|
Ultraviolet Rays | 4 | 2019 | 1060 | 0.210 |
Why?
|
Logistic Models | 7 | 2018 | 13408 | 0.210 |
Why?
|
United States Food and Drug Administration | 3 | 2019 | 1584 | 0.210 |
Why?
|
Patient Participation | 1 | 2011 | 1457 | 0.210 |
Why?
|
DNA, Viral | 2 | 2012 | 2225 | 0.210 |
Why?
|
Prevalence | 9 | 2024 | 15226 | 0.210 |
Why?
|
Enhancer Elements, Genetic | 2 | 2020 | 1341 | 0.210 |
Why?
|
Morbidity | 3 | 2016 | 1769 | 0.200 |
Why?
|
Fibrosarcoma | 1 | 2004 | 348 | 0.200 |
Why?
|
Anticholesteremic Agents | 1 | 2009 | 979 | 0.200 |
Why?
|
Endorphins | 1 | 2021 | 75 | 0.200 |
Why?
|
Eosinophilia | 1 | 2006 | 541 | 0.200 |
Why?
|
Antioxidants | 1 | 2009 | 1663 | 0.200 |
Why?
|
Nose | 1 | 2005 | 509 | 0.200 |
Why?
|
Molecular Sequence Annotation | 2 | 2020 | 528 | 0.200 |
Why?
|
Blood Coagulation Disorders | 1 | 2004 | 337 | 0.190 |
Why?
|
Reference Values | 3 | 2017 | 4982 | 0.190 |
Why?
|
Eczema | 1 | 2023 | 231 | 0.180 |
Why?
|
Case-Control Studies | 7 | 2023 | 21746 | 0.180 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2022 | 941 | 0.180 |
Why?
|
Age Factors | 6 | 2018 | 18370 | 0.180 |
Why?
|
Receptors, Calcitriol | 2 | 2012 | 350 | 0.180 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2703 | 0.180 |
Why?
|
Face | 3 | 2019 | 994 | 0.180 |
Why?
|
Thymidine Phosphorylase | 1 | 1999 | 15 | 0.180 |
Why?
|
Infant, Premature, Diseases | 1 | 2006 | 706 | 0.180 |
Why?
|
Xeroderma Pigmentosum | 1 | 2019 | 31 | 0.180 |
Why?
|
Electronics | 1 | 2021 | 322 | 0.180 |
Why?
|
Hypertension | 3 | 2018 | 8480 | 0.170 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 188 | 0.170 |
Why?
|
Health Maintenance Organizations | 2 | 2014 | 642 | 0.170 |
Why?
|
Neoplasm Staging | 7 | 2023 | 11031 | 0.170 |
Why?
|
Ascorbic Acid | 1 | 2022 | 651 | 0.170 |
Why?
|
Drug Costs | 2 | 2017 | 1105 | 0.170 |
Why?
|
CD4 Lymphocyte Count | 2 | 2017 | 2559 | 0.170 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 3616 | 0.170 |
Why?
|
HIV Infections | 2 | 2017 | 16718 | 0.170 |
Why?
|
Polymorphism, Genetic | 3 | 2019 | 4328 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9239 | 0.160 |
Why?
|
Insurance Claim Review | 2 | 2015 | 720 | 0.160 |
Why?
|
Papillomavirus Infections | 4 | 2019 | 1587 | 0.160 |
Why?
|
Massachusetts | 3 | 2021 | 8663 | 0.160 |
Why?
|
Photochemotherapy | 2 | 2021 | 807 | 0.160 |
Why?
|
Computational Biology | 2 | 2020 | 3521 | 0.150 |
Why?
|
Histocompatibility Testing | 1 | 2019 | 741 | 0.150 |
Why?
|
Head and Neck Neoplasms | 2 | 2014 | 2734 | 0.150 |
Why?
|
Immunocompromised Host | 3 | 2019 | 847 | 0.150 |
Why?
|
Receptor, Melanocortin, Type 1 | 1 | 2017 | 76 | 0.150 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 1038 | 0.150 |
Why?
|
Comorbidity | 4 | 2018 | 10388 | 0.150 |
Why?
|
Intention to Treat Analysis | 1 | 2018 | 426 | 0.150 |
Why?
|
Pemphigus | 2 | 2008 | 103 | 0.150 |
Why?
|
Symbiosis | 1 | 2019 | 287 | 0.150 |
Why?
|
Off-Label Use | 1 | 2018 | 169 | 0.150 |
Why?
|
Ultraviolet Therapy | 1 | 2017 | 81 | 0.140 |
Why?
|
Administration, Cutaneous | 1 | 2018 | 711 | 0.140 |
Why?
|
Injections, Subcutaneous | 1 | 2018 | 666 | 0.140 |
Why?
|
Survival Rate | 5 | 2017 | 12788 | 0.140 |
Why?
|
Feeding Behavior | 1 | 2009 | 3188 | 0.140 |
Why?
|
Surgical Flaps | 1 | 2005 | 1640 | 0.140 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2020 | 430 | 0.140 |
Why?
|
Physicians, Primary Care | 2 | 2013 | 591 | 0.130 |
Why?
|
Aspergillus | 1 | 2015 | 85 | 0.130 |
Why?
|
Spondylarthritis | 1 | 2016 | 62 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2022 | 592 | 0.130 |
Why?
|
Multifactorial Inheritance | 2 | 2019 | 1194 | 0.130 |
Why?
|
Kava | 1 | 2014 | 2 | 0.130 |
Why?
|
Evidence-Based Practice | 1 | 2019 | 500 | 0.130 |
Why?
|
Policy | 1 | 2019 | 508 | 0.130 |
Why?
|
Patient Selection | 3 | 2013 | 4215 | 0.130 |
Why?
|
Sebaceous Glands | 1 | 2014 | 41 | 0.130 |
Why?
|
Sunburn | 2 | 2018 | 155 | 0.130 |
Why?
|
Spondylitis, Ankylosing | 1 | 2016 | 156 | 0.130 |
Why?
|
Pharmaceutical Services | 1 | 2016 | 140 | 0.130 |
Why?
|
Paraneoplastic Syndromes | 1 | 2016 | 151 | 0.120 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1613 | 0.120 |
Why?
|
Child, Preschool | 7 | 2018 | 41006 | 0.120 |
Why?
|
Intention | 1 | 2017 | 341 | 0.120 |
Why?
|
Causality | 1 | 2021 | 1275 | 0.120 |
Why?
|
Vaccines | 1 | 2023 | 822 | 0.120 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 3255 | 0.120 |
Why?
|
Parents | 2 | 2018 | 3407 | 0.120 |
Why?
|
Plant Preparations | 1 | 2014 | 94 | 0.120 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2016 | 336 | 0.120 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2017 | 4420 | 0.120 |
Why?
|
Tumor Virus Infections | 1 | 2016 | 452 | 0.120 |
Why?
|
Genotype | 3 | 2018 | 12951 | 0.110 |
Why?
|
Aspergillosis | 1 | 2015 | 235 | 0.110 |
Why?
|
Random Allocation | 1 | 2018 | 2429 | 0.110 |
Why?
|
Severity of Illness Index | 4 | 2023 | 15540 | 0.110 |
Why?
|
Disease Progression | 3 | 2020 | 13284 | 0.110 |
Why?
|
Extremities | 1 | 2019 | 865 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2018 | 681 | 0.110 |
Why?
|
Documentation | 1 | 2019 | 871 | 0.110 |
Why?
|
Head | 1 | 2019 | 880 | 0.110 |
Why?
|
Systematized Nomenclature of Medicine | 1 | 2013 | 36 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2022 | 1239 | 0.110 |
Why?
|
Internet | 2 | 2017 | 3064 | 0.110 |
Why?
|
Treatment Outcome | 9 | 2023 | 63114 | 0.110 |
Why?
|
Prospective Studies | 8 | 2018 | 53288 | 0.110 |
Why?
|
Health Care Surveys | 2 | 2017 | 2453 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2017 | 547 | 0.110 |
Why?
|
Quantitative Trait Loci | 1 | 2020 | 2019 | 0.110 |
Why?
|
Lip Neoplasms | 1 | 2012 | 37 | 0.110 |
Why?
|
Cryosurgery | 2 | 2021 | 453 | 0.110 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11366 | 0.110 |
Why?
|
Phytotherapy | 1 | 2014 | 298 | 0.110 |
Why?
|
Hydrochlorothiazide | 1 | 2012 | 98 | 0.110 |
Why?
|
Antirheumatic Agents | 1 | 2022 | 1339 | 0.100 |
Why?
|
Nifedipine | 1 | 2012 | 226 | 0.100 |
Why?
|
Sunscreening Agents | 1 | 2012 | 132 | 0.100 |
Why?
|
Clinical Coding | 1 | 2013 | 171 | 0.100 |
Why?
|
Electrosurgery | 1 | 2012 | 58 | 0.100 |
Why?
|
Child | 10 | 2018 | 77709 | 0.100 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2015 | 280 | 0.100 |
Why?
|
Quality of Life | 2 | 2017 | 12804 | 0.100 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.100 |
Why?
|
Drug Eruptions | 1 | 2014 | 297 | 0.100 |
Why?
|
International Classification of Diseases | 2 | 2015 | 867 | 0.100 |
Why?
|
Drug Utilization | 1 | 2017 | 1183 | 0.100 |
Why?
|
Private Practice | 1 | 2011 | 154 | 0.100 |
Why?
|
Repressor Proteins | 1 | 2022 | 3023 | 0.090 |
Why?
|
Sensitivity and Specificity | 4 | 2015 | 14722 | 0.090 |
Why?
|
Immunity | 1 | 2017 | 1012 | 0.090 |
Why?
|
Fees and Charges | 1 | 2011 | 195 | 0.090 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 2010 | 40 | 0.090 |
Why?
|
Fetal Blood | 1 | 2017 | 1318 | 0.090 |
Why?
|
Gastrectomy | 1 | 2015 | 663 | 0.090 |
Why?
|
Marital Status | 1 | 2011 | 437 | 0.090 |
Why?
|
Family | 2 | 2011 | 3147 | 0.090 |
Why?
|
Biopsy | 3 | 2013 | 6756 | 0.090 |
Why?
|
Gene Frequency | 1 | 2017 | 3588 | 0.090 |
Why?
|
Neoplasms, Basal Cell | 1 | 2009 | 31 | 0.090 |
Why?
|
Calcium, Dietary | 1 | 2012 | 526 | 0.090 |
Why?
|
Exanthema | 1 | 2014 | 501 | 0.090 |
Why?
|
Pulmonary Embolism | 1 | 2022 | 2376 | 0.090 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2014 | 709 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2278 | 0.090 |
Why?
|
Cluster Analysis | 1 | 2016 | 2715 | 0.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2023 | 3923 | 0.090 |
Why?
|
Computer-Assisted Instruction | 1 | 2012 | 365 | 0.090 |
Why?
|
Professional Competence | 1 | 2012 | 447 | 0.090 |
Why?
|
Motivation | 1 | 2019 | 1971 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6538 | 0.080 |
Why?
|
Sex Characteristics | 1 | 2019 | 2585 | 0.080 |
Why?
|
Northwestern United States | 1 | 2008 | 20 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2018 | 1637 | 0.080 |
Why?
|
Survival Analysis | 3 | 2016 | 10252 | 0.080 |
Why?
|
Longitudinal Studies | 2 | 2018 | 13989 | 0.080 |
Why?
|
Viral Load | 1 | 2017 | 3299 | 0.080 |
Why?
|
Family Relations | 1 | 2010 | 321 | 0.080 |
Why?
|
Antibodies, Monoclonal | 2 | 2017 | 9274 | 0.080 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6895 | 0.080 |
Why?
|
Postoperative Hemorrhage | 1 | 2011 | 413 | 0.080 |
Why?
|
Hedgehog Proteins | 1 | 2012 | 783 | 0.080 |
Why?
|
Eggs | 1 | 2009 | 184 | 0.080 |
Why?
|
Skin Transplantation | 2 | 2004 | 1074 | 0.080 |
Why?
|
Food | 1 | 2012 | 771 | 0.080 |
Why?
|
Linear Models | 1 | 2018 | 5952 | 0.080 |
Why?
|
Predictive Value of Tests | 3 | 2013 | 15076 | 0.070 |
Why?
|
Head-Down Tilt | 1 | 2007 | 64 | 0.070 |
Why?
|
Methotrexate | 1 | 2013 | 1727 | 0.070 |
Why?
|
Health Personnel | 2 | 2017 | 3218 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3528 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.070 |
Why?
|
Sweat Gland Diseases | 1 | 2006 | 11 | 0.070 |
Why?
|
Lung Transplantation | 1 | 2015 | 1153 | 0.070 |
Why?
|
Cause of Death | 1 | 2017 | 3584 | 0.070 |
Why?
|
Psychological Theory | 1 | 2007 | 168 | 0.070 |
Why?
|
Torsion Abnormality | 1 | 2007 | 93 | 0.070 |
Why?
|
Eosinophil-Derived Neurotoxin | 1 | 2006 | 13 | 0.070 |
Why?
|
Eosinophil Major Basic Protein | 1 | 2006 | 14 | 0.070 |
Why?
|
Transcription, Genetic | 1 | 2020 | 7722 | 0.070 |
Why?
|
Neoplasms | 4 | 2021 | 21683 | 0.070 |
Why?
|
Program Development | 1 | 2012 | 1316 | 0.070 |
Why?
|
Eccrine Glands | 1 | 2006 | 45 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2012 | 2948 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7279 | 0.070 |
Why?
|
Milk | 1 | 2009 | 450 | 0.070 |
Why?
|
Nutrition Surveys | 1 | 2012 | 1660 | 0.070 |
Why?
|
Mupirocin | 1 | 2006 | 56 | 0.070 |
Why?
|
Fishes | 1 | 2009 | 569 | 0.070 |
Why?
|
Genetic Counseling | 1 | 2009 | 600 | 0.070 |
Why?
|
Immunotherapy | 1 | 2021 | 4445 | 0.070 |
Why?
|
Behavior Therapy | 1 | 2011 | 865 | 0.070 |
Why?
|
Algorithms | 4 | 2016 | 13881 | 0.070 |
Why?
|
Infant | 4 | 2014 | 35136 | 0.070 |
Why?
|
Genetic Variation | 1 | 2021 | 6544 | 0.070 |
Why?
|
Phylogeny | 2 | 2015 | 2803 | 0.060 |
Why?
|
Homeodomain Proteins | 1 | 2015 | 2421 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2019 | 4479 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2015 | 1333 | 0.060 |
Why?
|
Body Mass Index | 2 | 2021 | 12720 | 0.060 |
Why?
|
Hair | 1 | 2008 | 483 | 0.060 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12245 | 0.060 |
Why?
|
Infant, Newborn | 3 | 2014 | 25625 | 0.060 |
Why?
|
Faculty, Medical | 1 | 2012 | 1181 | 0.060 |
Why?
|
Hamartoma | 1 | 2006 | 238 | 0.060 |
Why?
|
Acetaminophen | 1 | 2008 | 545 | 0.060 |
Why?
|
Bandages | 1 | 2006 | 266 | 0.060 |
Why?
|
Curriculum | 1 | 2017 | 3605 | 0.060 |
Why?
|
Cervix Uteri | 1 | 2007 | 590 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2012 | 2258 | 0.060 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 329 | 0.060 |
Why?
|
Sodium Chloride | 1 | 2006 | 625 | 0.060 |
Why?
|
Animals | 7 | 2021 | 168757 | 0.060 |
Why?
|
Mortality | 1 | 2015 | 2864 | 0.060 |
Why?
|
Signal Transduction | 2 | 2019 | 23403 | 0.060 |
Why?
|
Arteriovenous Malformations | 1 | 2006 | 396 | 0.060 |
Why?
|
DNA Damage | 1 | 2012 | 2432 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8428 | 0.050 |
Why?
|
Genetic Testing | 2 | 2019 | 3444 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2013 | 2899 | 0.050 |
Why?
|
Graft Rejection | 1 | 2015 | 4397 | 0.050 |
Why?
|
Risk Reduction Behavior | 1 | 2009 | 1125 | 0.050 |
Why?
|
Cyclooxygenase 2 | 1 | 2004 | 611 | 0.050 |
Why?
|
Disclosure | 1 | 2007 | 736 | 0.050 |
Why?
|
Health Behavior | 2 | 2017 | 2636 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5137 | 0.050 |
Why?
|
New York | 1 | 2023 | 886 | 0.050 |
Why?
|
Aspirin | 1 | 2013 | 3282 | 0.050 |
Why?
|
Diclofenac | 1 | 2021 | 71 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4567 | 0.050 |
Why?
|
Necrosis | 1 | 2005 | 1643 | 0.050 |
Why?
|
Education, Medical | 1 | 2012 | 1721 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2007 | 12959 | 0.050 |
Why?
|
Vaccination | 2 | 2023 | 3278 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2015 | 3712 | 0.050 |
Why?
|
Life Style | 1 | 2012 | 3835 | 0.050 |
Why?
|
Mucous Membrane | 1 | 2023 | 673 | 0.040 |
Why?
|
Surgical Mesh | 1 | 2002 | 276 | 0.040 |
Why?
|
Isoenzymes | 1 | 2004 | 1726 | 0.040 |
Why?
|
Mutation | 3 | 2019 | 29786 | 0.040 |
Why?
|
Primary Health Care | 2 | 2017 | 4558 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 25043 | 0.040 |
Why?
|
Patient-Centered Care | 1 | 2009 | 1439 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 778 | 0.040 |
Why?
|
Hand | 1 | 2004 | 884 | 0.040 |
Why?
|
Clinical Competence | 1 | 2013 | 4687 | 0.040 |
Why?
|
Keratoacanthoma | 1 | 2017 | 33 | 0.040 |
Why?
|
Photosensitivity Disorders | 1 | 2017 | 78 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13102 | 0.040 |
Why?
|
Retinoids | 1 | 2017 | 101 | 0.040 |
Why?
|
Hair Follicle | 1 | 1999 | 209 | 0.040 |
Why?
|
PUVA Therapy | 1 | 1997 | 98 | 0.040 |
Why?
|
Cell Size | 1 | 1999 | 643 | 0.040 |
Why?
|
Antibody Specificity | 1 | 1999 | 1095 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6364 | 0.040 |
Why?
|
Time Factors | 3 | 2017 | 40075 | 0.040 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7181 | 0.040 |
Why?
|
Communication | 1 | 2010 | 3749 | 0.040 |
Why?
|
Infant, Premature | 1 | 2006 | 2044 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 1999 | 1799 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2015 | 15295 | 0.030 |
Why?
|
Societies, Medical | 2 | 2018 | 3743 | 0.030 |
Why?
|
Niacinamide | 1 | 2017 | 417 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2023 | 20822 | 0.030 |
Why?
|
Vitamin B Complex | 1 | 2017 | 288 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2009 | 4234 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2004 | 1855 | 0.030 |
Why?
|
Sampling Studies | 1 | 2016 | 623 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3282 | 0.030 |
Why?
|
Public Health | 1 | 2007 | 2603 | 0.030 |
Why?
|
Cost of Illness | 1 | 2024 | 1859 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2018 | 594 | 0.030 |
Why?
|
Pregnancy Trimester, Second | 1 | 2017 | 732 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 640 | 0.030 |
Why?
|
Computers | 1 | 2016 | 612 | 0.030 |
Why?
|
Oncogenes | 1 | 2019 | 1265 | 0.030 |
Why?
|
Computer User Training | 1 | 2012 | 19 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7785 | 0.030 |
Why?
|
Erythema | 1 | 2014 | 257 | 0.030 |
Why?
|
Pregnancy Trimester, First | 1 | 2017 | 853 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1770 | 0.030 |
Why?
|
Reimbursement Mechanisms | 1 | 2018 | 670 | 0.030 |
Why?
|
Pharmacoepidemiology | 1 | 2015 | 323 | 0.030 |
Why?
|
Visual Pathways | 1 | 1996 | 565 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11124 | 0.030 |
Why?
|
Drugs, Generic | 1 | 2016 | 421 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2018 | 1783 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8642 | 0.020 |
Why?
|
Papillomavirus Vaccines | 1 | 2017 | 491 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2016 | 1641 | 0.020 |
Why?
|
Washington | 1 | 2012 | 313 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 6314 | 0.020 |
Why?
|
Primary Prevention | 1 | 2018 | 1167 | 0.020 |
Why?
|
RNA, Viral | 1 | 2019 | 2902 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2015 | 730 | 0.020 |
Why?
|
Phototherapy | 1 | 2013 | 377 | 0.020 |
Why?
|
Pattern Recognition, Visual | 1 | 1996 | 824 | 0.020 |
Why?
|
Hospitalization | 2 | 2023 | 10262 | 0.020 |
Why?
|
Codon | 1 | 2012 | 611 | 0.020 |
Why?
|
Ibuprofen | 1 | 2012 | 236 | 0.020 |
Why?
|
Research | 1 | 2018 | 1999 | 0.020 |
Why?
|
Coccidioidomycosis | 1 | 1970 | 36 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2016 | 1205 | 0.020 |
Why?
|
Photic Stimulation | 1 | 1996 | 2025 | 0.020 |
Why?
|
Histoplasmosis | 1 | 1970 | 66 | 0.020 |
Why?
|
Prenatal Care | 1 | 2017 | 1092 | 0.020 |
Why?
|
Michigan | 1 | 2009 | 350 | 0.020 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2008 | 69 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2018 | 2942 | 0.020 |
Why?
|
Disease Management | 1 | 2018 | 2459 | 0.020 |
Why?
|
Skin Tests | 1 | 1970 | 613 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2004 | 7880 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4851 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 1788 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7799 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2011 | 1184 | 0.020 |
Why?
|
Psychology | 1 | 2007 | 356 | 0.020 |
Why?
|
Mouth Mucosa | 1 | 2008 | 434 | 0.020 |
Why?
|
Family Characteristics | 1 | 2010 | 1000 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2001 | 7913 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2015 | 5078 | 0.020 |
Why?
|
Graft Survival | 1 | 2015 | 3737 | 0.020 |
Why?
|
Mice | 3 | 2021 | 81183 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2007 | 511 | 0.020 |
Why?
|
Postmenopause | 1 | 2013 | 2461 | 0.010 |
Why?
|
Health Expenditures | 1 | 2016 | 2348 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8388 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 11524 | 0.010 |
Why?
|
Medicaid | 1 | 2016 | 2736 | 0.010 |
Why?
|
Regression Analysis | 1 | 2012 | 6459 | 0.010 |
Why?
|
Lipids | 1 | 2013 | 3305 | 0.010 |
Why?
|
Varicose Ulcer | 1 | 2002 | 52 | 0.010 |
Why?
|
Precancerous Conditions | 1 | 2007 | 975 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 19905 | 0.010 |
Why?
|
Health Surveys | 1 | 1970 | 4037 | 0.010 |
Why?
|
Blood Glucose | 1 | 2013 | 6256 | 0.010 |
Why?
|
Diabetic Foot | 1 | 2002 | 355 | 0.010 |
Why?
|
Medicare | 1 | 2016 | 6566 | 0.010 |
Why?
|
Blood Pressure | 1 | 2013 | 8554 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1997 | 335 | 0.010 |
Why?
|
Pregnancy | 1 | 2017 | 29144 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 9959 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 6773 | 0.010 |
Why?
|
Wound Healing | 1 | 2002 | 2785 | 0.010 |
Why?
|
Histoplasmin | 1 | 1970 | 2 | 0.010 |
Why?
|
Mass Chest X-Ray | 1 | 1970 | 16 | 0.010 |
Why?
|
Coccidioides | 1 | 1970 | 17 | 0.010 |
Why?
|
Histoplasma | 1 | 1970 | 41 | 0.010 |
Why?
|
Soil Microbiology | 1 | 1970 | 87 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 1996 | 35421 | 0.010 |
Why?
|
Tuberculin Test | 1 | 1970 | 214 | 0.010 |
Why?
|
Climate | 1 | 1970 | 147 | 0.010 |
Why?
|
Blood Cell Count | 1 | 1970 | 403 | 0.010 |
Why?
|
Visual Cortex | 1 | 1996 | 1149 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1997 | 6171 | 0.000 |
Why?
|
Sputum | 1 | 1970 | 476 | 0.000 |
Why?
|
Occupations | 1 | 1970 | 517 | 0.000 |
Why?
|
Iran | 1 | 1970 | 708 | 0.000 |
Why?
|
Antigens | 1 | 1970 | 1466 | 0.000 |
Why?
|
Brain Mapping | 1 | 1996 | 6669 | 0.000 |
Why?
|
Rural Population | 1 | 1970 | 2210 | 0.000 |
Why?
|